Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n' Bears Report…
21
Jun
The Australian reports that Race Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients.
Read the full article here.
